Article
Oncology
Volker Moebus, Hans-Joachim Lueck, Ekkehart Ladda, Peter Klare, Marcus Schmidt, Andreas Schneeweiss, Eva-Maria Grischke, Grischa Wachsmann, Helmut Forstbauer, Michael Untch, Frederik Marme, Jens-Uwe Blohmer, Christian Jackisch, Jens Huober, Elmar Stickeler, Mattea Reinisch, Theresa Link, Bruno Sinn, Wolfgang Janni, Carsten Denkert, Jenny Furlanetto, Knut Engels, Christine Solbach, Sabine Schmatloch, Julia Rey, Nicole Burchardi, Sibylle Loibl
Summary: The interim analysis of the GAIN-2 trial showed no difference in invasive disease-free survival between intense dose dense (idd) and tailored dose-dense chemotherapy regimens, but tailoring treatment improved outcomes for patients with HR+/HER2-, lobular cancer, and those aged ≤50 years.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Mattea Reinisch, Simona Bruzas, Oleg Gluz, Beyhan Ataseven, Peter Schmid, Javier Cortes, Jens-Uwe Blohmer, Satyendra Shenoy, Mark H. Dyson, Christine Dittmer-Grabowski, Ouafaa Chiari, Hakima Harrach, Daniel Gebauer, Alexander Traut, Sherko Kuemmel
Summary: This study explored the expression of 758 genes in early breast cancer patients and identified several genes and immune markers associated with prognosis. The study also found two genes that played a role in chemotherapy efficacy and survival. Therefore, multigene expression analysis has the potential for prognosis and prediction in early breast cancer.
MOLECULAR ONCOLOGY
(2023)
Article
Oncology
Kim R. M. Blenman, Michal Marczyk, Thomas Karn, Tao Qing, Xiaotong Li, Vignesh Gunasekharan, Vesal Yaghoobi, Yalai Bai, Eiman Y. Ibrahim, Tristen Park, Andrea Silber, Denise M. Wolf, Emily Reisenbichler, Carsten Denkert, Bruno V. Sinn, Mariya Rozenblit, Julia Foldi, David L. Rimm, Sibylle Loibl, Lajos Pusztai
Summary: This study examined gene expression, germline variant, and somatic mutation features associated with pathologic response to neoadjuvant durvalumab plus chemotherapy in basal-like triple-negative breast cancer. The results showed differences in gene expression and pathway enrichment between cases with different pathologic responses, with immune-rich cases being associated with macrophages, activated B cells, and T cells, while immune-poor cases were associated with other signaling pathways. The findings contribute to a better understanding and prediction of the efficacy of this treatment regimen.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Parth Sharma, Josh Thomas Georgy, Anand George Andrews, Ajoy Oommen John, Anjana Joel, Raju Titus Chacko, Prasanna Samuel Premkumar, Ashish Singh
Summary: This study investigated the prevalence of chemotherapy-related anemia and the associated risk factors in Indian breast cancer patients receiving dose-dense chemotherapy. The results showed that anemia is a common complication of dose-dense chemotherapy, leading to treatment delay and increased cost. Low-grade tumor, grade 3 or 4 thrombocytopenia, and grade 2 or higher anemia after two cycles of chemotherapy were identified as risk factors for blood transfusions during treatment.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Tihana Boraska Jelavic, Mario Podrug, Marija Ban, Ingrid Belac Lovasic, Zvonimir Curic, Eduard Vrdoljak
Summary: The study aimed to explore red blood cell changes during neoadjuvant dose-dense chemotherapy in breast cancer patients, and to investigate the role of macrocytosis as a predictive biomarker for pathological complete response and disease-free survival. Findings showed an increase in mean corpuscular volume and induction of macrocytosis in 38% of patients, but macrocytosis did not correlate with DFS. Further research is needed to determine the relevance of macrocytosis induction during breast cancer chemotherapy.
Article
Oncology
Yin Liu, Lei Fan, Zhong-Hua Wang, Zhi-Ming Shao
Summary: This study evaluated the efficacy and safety of nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide as neoadjuvant therapy in patients with triple-negative breast cancer, showing promising anti-tumor activity and acceptable tolerability.
Article
Medicine, Research & Experimental
Dorel Popovici, Cristina Oprean, Sorin Saftescu, Alina Negru, Mihnea Munteanu, Horia T. Stanca, Adrian Teodoru, Simona Stanca, Serban Negru
Summary: The aim of this study was to examine the feasibility and toxicity of neoadjuvant dose-dense chemotherapy in non-metastatic breast cancer women. Inclusion criteria such as age, treatment intent, and physiological indicators were used in the study.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Oncology
Sylvie Giacchetti, Lilith Faucheux, Charlotte Gardair, Caroline Cuvier, Anne de Roquancourt, Luca Campedel, David Groheux, Cedric de Bazelaire, Jacqueline Lehmann-Che, Catherine Miquel, Laurence Cahen Doidy, Malika Amellou, Isabelle Madelaine, Fabien Reyal, Laetitia Someil, Hamid Hocini, Christophe Hennequin, Luis Teixeira, Marc Espie, Sylvie Chevret, Vassili Soumelis, Anne-Sophie Hamy
Summary: This study aimed to investigate the changes in TIL levels after neoadjuvant chemotherapy in TNBC patients and evaluate the factors associated with these changes and oncological outcomes. The results suggest that patients with persistently high TIL levels after NAC have a higher risk of relapse and death.
Article
Oncology
Xing Wang, Jiwei Wang, Yingjian He, Jinfeng Li, Tianfeng Wang, Tao Ouyang, Zhaoqing Fan
Summary: The study found that dose-dense neoadjuvant chemotherapy resulted in higher rates of pathological complete response in patients with triple-negative breast cancer compared to conventional chemotherapy. However, there was no significant difference in survival outcomes between the two groups.
CLINICAL BREAST CANCER
(2023)
Article
Oncology
Meng Xiu, Pin Zhang, Xiang Wang, Ying Fan, Qiao Li, Qing Li, Jiayu Wang, Lin Dong, Yang Luo, Peng Yuan, Fei Ma, Binghe Xu
Summary: This study explores the long-term benefits of platinum-based neoadjuvant chemotherapy for triple-negative breast cancer and finds that this treatment approach is associated with superior 4-year recurrence-free survival and overall survival compared to standard adjuvant chemotherapy.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Chris Lomma, HuiJun Chih, Arlene Chan
Summary: This study compares adverse events of surgery, radiotherapy, and chemotherapy in 280 patients with (55) and without (225) obesity receiving dense adjuvant chemotherapy. The results showed that obesity was not associated with higher rates of surgical or chemotherapy toxicity, but may be associated with radiotherapy-related skin toxicity. This study supports the use of dose dense chemotherapy based on actual body weight in patients with obesity.
CLINICAL BREAST CANCER
(2023)
Article
Oncology
Lize Wang, Yang Zhang, Yingjian He, Jinfeng Li, Tianfeng Wang, Yuntao Xie, Zhaoqing Fan, Tao Ouyang
Summary: Dose-dense neoadjuvant chemotherapy with trastuzumab may improve pathologic complete remission rate and lymph node pCR rate in patients with HER2-positive breast cancer, especially showing better survival outcomes in younger patients.
Article
Oncology
Jeanine E. Vasmel, Celien P. H. Vreuls, Quirine F. Manson, Ramona K. Charaghvandi, Joost van Gorp, A. M. Gijs van Leeuwen, Paul J. van Diest, Helena M. Verkooijen, H. J. G. Desiree van den Bongard
Summary: This study evaluated the changes in tumor-infiltrating lymphocytes (TILs) in low-risk patients with breast cancer after preoperative partial breast irradiation (PBI), and found that the number of TILs decreased in tumor tissue after PBI in this limited cohort. There was no significant difference in preirradiation TILs numbers between responders and nonresponders, suggesting that preirradiation TILs may not be a predictive factor for treatment response.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Andreas Schneeweiss, Laura L. Michel, Volker Moebus, Hans Tesch, Peter Klare, Eric Hahnen, Carsten Denkert, Karin Kast, Esther Pohl-Rescigno, Claus Hanusch, Theresa Link, Michael Untch, Christian Jackisch, Jens-Uwe Blohmer, Peter A. Fasching, Christine Solbach, Rita K. Schmutzler, Jens Huober, Kerstin Rhiem, Valentina Nekljudova, Kristina Luebbe, Sibylle Loibl
Summary: GeparOcto demonstrated that intense dose-dense chemotherapy with iddEPC is comparable to weekly chemotherapy with PM(Cb) in achieving pathological complete response (pCR) in high-risk early breast cancer, specifically triple negative breast cancer (TNBC). The study found no significant difference in overall survival (OS) and invasive disease-free survival (iDFS) between the two treatment regimens for the entire cohort. However, HR+/HER2+ patients benefited significantly in terms of iDFS and OS from iddEPC.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Hannah C. Timmins, Tiffany Li, Terry Trinh, Matthew C. Kiernan, Michelle Harrison, Frances Boyle, Michael Friedlander, David Goldstein, Susanna B. Park
Summary: The study reveals that weekly paclitaxel treatment can induce neuropathy early on and patients may require closer monitoring. Dose reduction does not necessarily result in better neuropathy outcomes, with individual risk factors also playing a significant role.